Amivantamab
Amivantamab in ACC
Trisha Wise-Draper (investigator) · Phase 2 · Active, not recruiting · Enrollment 21
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Amivantamab | ACC (n = 21) | not stated in source | Single arm | n/r | responders: 1 patients (of 21), results posted 05.08.2026median progression-free survival: 4.6 months, results posted 05.08.2026 |